First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector–Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults

BACKGROUND: Respiratory syncytial virus (RSV) disease is a major cause of infant morbidity and mortality. This Phase I, randomized, observer-blind, placebo- and active-controlled study evaluated an investigational vaccine against RSV (ChAd155-RSV) using the viral vector chimpanzee-adenovirus-155, en...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicconi, Paola, Jones, Claire, Sarkar, Esha, Silva-Reyes, Laura, Klenerman, Paul, de Lara, Catherine, Hutchings, Claire, Moris, Philippe, Janssens, Michel, Fissette, Laurence A, Picciolato, Marta, Leach, Amanda, Gonzalez-Lopez, Antonio, Dieussaert, Ilse, Snape, Matthew D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201425/
https://www.ncbi.nlm.nih.gov/pubmed/31340042
http://dx.doi.org/10.1093/cid/ciz653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201425/
https://www.ncbi.nlm.nih.gov/pubmed/31340042
http://dx.doi.org/10.1093/cid/ciz653

Ejemplares similares